The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 744 Metabolic Health articles
Silicon Valley's biohacking craze has hit Temu, where peptides are sold for pennies, raising alarms about safety and purity. From BPC-157 vials to questionable GLP-1s, these products bypass rigorous testing. A closer look reveals why this mainstream shift could be disastrous for health.
A 33-year-old GP tried Mounjaro for obesity and was stunned by more than just weight loss—his 'food noise' vanished, alcohol interest dropped, and mood stabilized. After shedding almost two stone in three months, urges returned upon stopping, highlighting obesity's chronic nature. Now back on 5mg, he emphasizes long-term strategies beyond medication.
For the first time, researchers have demonstrated that tirzepatide—the key ingredient in Mounjaro—slashes voluntary alcohol consumption by more than half in rodents while curbing relapse-like drinking. Published in eBioMedicine, this University of Gothenburg study highlights effects on the brain's reward system, including dopamine modulation in the lateral septum. These findings build on prior semaglutide research and suggest potential for alcohol use disorder therapies.
Wall Street fixates on GLP-1 giants like Novo Nordisk's Ozempic and Eli Lilly, but Intuitive Surgical continues to thrive with its da Vinci surgical robots. With 11,106 systems installed by end of 2025 and procedures up 18%, this device maker is set for growth regardless of the weight loss drug race. Learn why investors should consider ISRG shares.
The aging population's Silver Tsunami is reshaping global economies, but the Longevity Investors Lunch offers a beacon of innovation. From ultra-personalized medicine to bio-avatars and surging GLP-1 valuations, investors are betting billions on extending healthy lifespans. Yet, warnings about risky supplements highlight the path ahead.
Hims & Hers aimed to disrupt the GLP-1 market with a cheap oral semaglutide pill, but faced swift FDA backlash and a patent lawsuit from Novo Nordisk. The retreat highlights regulatory risks for compounders as branded supplies stabilize. This analysis reveals challenges in oral GLP-1 production and future paths for telehealth weight loss offerings.
New research from Veterans' Affairs shows Ozempic and Wegovy users face double the risk of NAION—a serious vision loss condition—compared to SGLT2i drugs. Published in JAMA Ophthalmology, the study urges doctors to warn patients about potential permanent blindness from semaglutide-based GLP-1 medications. As lawsuits mount, understand the implications for diabetes and weight management.
Eli Lilly has overtaken Novo Nordisk in the GLP-1 gold rush, with Mounjaro and Zepbound now holding 60% of the U.S. market versus Ozempic and Wegovy's 39%. Backed by blockbuster revenue growth and superior weight loss results in head-to-head studies, Lilly's tirzepatide drugs are reshaping obesity and diabetes treatment. Investors and patients alike are taking notice of this shift.
A superintendent pharmacist is urging Mounjaro users to take specific precautions when traveling on holiday, from buffet strategies to proper medication storage. Buffets pose unique challenges for GLP-1 users, and extreme temperatures in plane cargo holds can ruin pens. Get expert advice to keep your weight loss journey on track.
